PAP
KTTA icon

Persistent Asset Partners’s Pasithea Therapeutics KTTA Stock Holding History

Persistent Asset Partners’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Hold
290,555
– – 0.04% 250
2026
Q1 		$216K Hold
290,555
– – 0.08% 188
2025
Q4 		$375K Buy
+290,555
New +$255K 0.17% 158

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Persistent Asset Partners's KTTA Position: Q2 2026 in Review

Persistent Asset Partners held its Pasithea Therapeutics (KTTA) position steady in Q2 2026 at 290,555 shares worth $150K. The position accounts for 0.04% of the portfolio, ranked #250.

Persistent Asset Partners first reported a position in KTTA in Q4 2025 and has held it in 3 quarters since. The position peaked at $375K in Q4 2025. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Persistent Asset Partners held 290,555 shares of Pasithea Therapeutics worth $150K as of Q2 2026.
  • Persistent Asset Partners left its Pasithea Therapeutics share count unchanged in Q2 2026.
  • Pasithea Therapeutics made up 0.04% of Persistent Asset Partners's portfolio in Q2 2026, its #250 holding.
  • Persistent Asset Partners first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Pasithea Therapeutics position peaked at $375K in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.